

China approves world's first dual GCG/GLP-1 receptor for glycemic control in type 2 diabetes

22 September 2025 | News

Mazdutide receives approval from China's NMPA for glycemic control in adults with Type 2 Diabetes



Innovent Biologics, Inc. has announced that China's National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for glycemic control in adults with type 2 diabetes (T2D).

Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for glycemic control in adults with T2D. It is expected to support disease management for the vast T2D population in China, achieving comprehensive benefits in glycemic control, weight reduction and hepato-cardio-renal metabolic indicators.

China leads the world in diabetes prevalence, with 140 million adults affected (1 in 4 global cases). Diabetes is a chronic condition where prolonged hyperglycemia can lead to severe complications, such as cardiovascular diseases, nephropathy, retinopathy and neuropathy. These complications not only endanger patients' lives and health but also impose a significant economic burden on families and society.

Building upon the established effects of GLP-1 receptor agonists, dual GCG/GLP-1 receptor agonists simultaneously improve the two core pathogenic mechanisms of diabetes - insufficient insulin secretion and insulin resistance, thus, delivering comprehensive benefits beyond glycemic control, including weight loss, and hepato-cardio-renal metabolic improvements. As a safe, effective and convenient novel therapeutic option, mazdutide addresses the critical needs of long-term glucose management and complication prevention in T2D, actively supporting the realization of the "Healthy China 2030" vision.